Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Factors associated with high use of general practitioner and psychiatrist services among patients attending an addiction rehabilitation center.

Huỳnh C, Ngamini Ngui A, Kairouz S, Lesage A, Fleury MJ.

BMC Psychiatry. 2016 Jul 22;16:258. doi: 10.1186/s12888-016-0974-7.

2.

Understanding Patterns Of High-Cost Health Care Use Across Different Substance User Groups.

Gryczynski J, Schwartz RP, O'Grady KE, Restivo L, Mitchell SG, Jaffe JH.

Health Aff (Millwood). 2016 Jan;35(1):12-9. doi: 10.1377/hlthaff.2015.0618.

3.

Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC.

Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Review.

4.

A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.

Gastfriend DR.

Ann N Y Acad Sci. 2014 Oct;1327:112-30. doi: 10.1111/nyas.12538. Review.

5.

Integrating addiction treatment into primary care using mobile health technology: protocol for an implementation research study.

Quanbeck AR, Gustafson DH, Marsch LA, McTavish F, Brown RT, Mares ML, Johnson R, Glass JE, Atwood AK, McDowell H.

Implement Sci. 2014 May 29;9:65. doi: 10.1186/1748-5908-9-65.

6.

Patient perspectives of an integrated program of medical care and substance use treatment.

Drainoni ML, Farrell C, Sorensen-Alawad A, Palmisano JN, Chaisson C, Walley AY.

AIDS Patient Care STDS. 2014 Feb;28(2):71-81. doi: 10.1089/apc.2013.0179.

7.

Treatment for substance use disorder: opportunities and challenges under the affordable care act.

Tai B, Volkow ND.

Soc Work Public Health. 2013;28(3-4):165-74. doi: 10.1080/19371918.2013.758975.

8.

The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial.

Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):90-7. doi: 10.1016/j.drugalcdep.2012.08.009.

9.

Methadone dose, take home status, and hospital admission among methadone maintenance patients.

Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH, Alford DP.

J Addict Med. 2012 Sep;6(3):186-90.

10.

Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Schwarz R, Zelenev A, Bruce RD, Altice FL.

J Subst Abuse Treat. 2012 Dec;43(4):451-7. doi: 10.1016/j.jsat.2012.03.008.

11.

Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China.

Du J, Wang Z, Xie B, Zhao M.

Am J Drug Alcohol Abuse. 2012 May;38(3):228-32. doi: 10.3109/00952990.2011.643974.

12.

Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.

Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH.

J Viral Hepat. 2012 Jan;19(1):47-54. doi: 10.1111/j.1365-2893.2010.01411.x.

13.

Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan.

McCarty D, Perrin NA, Green CA, Polen MR, Leo MC, Lynch F.

Drug Alcohol Depend. 2010 Oct 1;111(3):235-40. doi: 10.1016/j.drugalcdep.2010.04.018.

14.

The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, Renner JA, Weiss L, Saxon AJ, Fiellin DA.

J Gen Intern Med. 2010 Sep;25(9):936-41. doi: 10.1007/s11606-010-1377-y.

15.

Never in care: characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV care.

Bell C, Metsch LR, Vogenthaler N, Cardenas G, Rodriguez A, Locascio V, Kuper T, Scharf E, Marquez A, Yohannan M, del Rio C.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):376-80. doi: 10.1097/QAI.0b013e3181d01d31.

16.

The case for chronic disease management for addiction.

Saitz R, Larson MJ, Labelle C, Richardson J, Samet JH.

J Addict Med. 2008 Jun;2(2):55-65.

17.

Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals.

Brady KA, Weiner M, Turner BJ.

J Infect. 2009 Jul;59(1):62-9. doi: 10.1016/j.jinf.2009.04.008.

18.

Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death.

Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO.

J Stud Alcohol Drugs. 2008 Nov;69(6):924-32.

19.

Factors affecting willingness to provide buprenorphine treatment.

Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA; BHIVES Collaborative..

J Subst Abuse Treat. 2009 Apr;36(3):244-51. doi: 10.1016/j.jsat.2008.06.006.

20.

Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions.

Korthuis PT, Josephs JS, Fleishman JA, Hellinger J, Himelhoch S, Chander G, Morse EB, Gebo KA; HIV Research Network..

J Subst Abuse Treat. 2008 Oct;35(3):294-303. doi: 10.1016/j.jsat.2007.11.005.

Items per page

Supplemental Content

Support Center